More recently, based on the sequencing results of large samples, it was found that about 60% to 80% of patients with grade II and III gliomas and most patients with secondary glioblastoma (GBM) had somatic mutations encoding isocitrate dehydrogenase genes, mainly IDH1 R132 mutation (53, 54). This evidence concerns the gene IDH1 and glioblastoma.